210
Participants
Start Date
February 22, 2023
Primary Completion Date
March 31, 2025
Study Completion Date
March 31, 2025
Durvalumab
Durvalumab IV (intravenous infusion)
Tremelimumab
Tremelimumab IV (intravenous infusion)
ACTIVE_NOT_RECRUITING
Research Site, Beijing
ACTIVE_NOT_RECRUITING
Research Site, Beijing
ACTIVE_NOT_RECRUITING
Research Site, Shenyang
ACTIVE_NOT_RECRUITING
Research Site, Harbin
ACTIVE_NOT_RECRUITING
Research Site, Shanghai
ACTIVE_NOT_RECRUITING
Research Site, Shanghai
ACTIVE_NOT_RECRUITING
Research Site, Nanjing
ACTIVE_NOT_RECRUITING
Research Site, Nanjing
ACTIVE_NOT_RECRUITING
Research Site, Beijing
ACTIVE_NOT_RECRUITING
Research Site, Zhangjiagang
ACTIVE_NOT_RECRUITING
Research Site, Tianjin
WITHDRAWN
Research Site, Tianjin
WITHDRAWN
Research Site, Tianjin
ACTIVE_NOT_RECRUITING
Research Site, Hangzhou
ACTIVE_NOT_RECRUITING
Research Site, Ningbo
ACTIVE_NOT_RECRUITING
Research Site, Wenzhou
ACTIVE_NOT_RECRUITING
Research Site, Fuzhou
COMPLETED
Research Site, Changsha
ACTIVE_NOT_RECRUITING
Research Site, Changsha
ACTIVE_NOT_RECRUITING
Research Site, Wuhan
ACTIVE_NOT_RECRUITING
Research Site, Wuhan
WITHDRAWN
Research Site, Zhengzhou
ACTIVE_NOT_RECRUITING
Research Site, Zhengzhou
ACTIVE_NOT_RECRUITING
Research Site, Guangzhou
ACTIVE_NOT_RECRUITING
Research Site, Guangzhou
ACTIVE_NOT_RECRUITING
Research Site, Guangzhou
ACTIVE_NOT_RECRUITING
Research Site, Guangzhou
ACTIVE_NOT_RECRUITING
Research Site, Chengdu
ACTIVE_NOT_RECRUITING
Research Site, Xi'an
ACTIVE_NOT_RECRUITING
Research Site, Nanjing
RECRUITING
Research Site, Jinan
ACTIVE_NOT_RECRUITING
Research Site, Beijing
Lead Sponsor
AstraZeneca
INDUSTRY